Anti-Infectives · LP-028
Cefalexin Capsules
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-028Anti-Infectives
- Generic identity
- CefalexinCapsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-028
- Generic identity
- Cefalexin
- Presentation
- Capsule
- Catalogue strength
- 250 mg; 500 mg
- Catalogue pack
- Blister 10 x 10 capsules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cefalexin/cephalexin.
- Dosage form: capsule.
- Proposed strengths: 250 mg and 500 mg.
- General proposed pack: blister 10 × 10 capsules.
Layer 02 · Unresolved product-specific fields
- Exact cefalexin compound/basis, capsule shell and fill composition.
- Strength-to-pack/SKU mapping if packs differ by strength.
- Whether opening capsules is permitted and the approved administration instructions.
- Approved indication, storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 250 mg | Capsule | — | General blister 10 × 10 capsules | Capsule composition and administration instructions require the exact controlled product documents. |
| B | 500 mg | Capsule | — | General blister 10 × 10 capsules | Capsule composition and administration instructions require the exact controlled product documents. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cefalexin, also spelled cephalexin, is a cephalosporin antibiotic used for selected susceptible bacterial infections. Its role depends on the organism and infection site; it should not be described as universally suitable for respiratory or urinary symptoms. Oral capsules and reconstituted liquid preparations have separate administration requirements. This page explains the ingredient for professional reference and does not establish approved Luang Pharma indications or product interchangeability.
Clinical context and therapeutic role
Treatment decisions consider clinical findings, local susceptibility patterns and whether microbiological investigation is required. Some urinary, skin and respiratory infections may fall within the clinical context of cefalexin, but the diagnosis and local guideline determine its place. A detailed history of antibiotic allergy is important. Kidney function, age and ability to use the selected formulation should be reviewed before a professional chooses the appropriate presentation.
Selected safety context
Hypersensitivity reactions, including anaphylaxis and severe skin reactions, can occur. A previous reaction to a cephalosporin or another beta-lactam antibiotic should be discussed before treatment. Diarrhoea, nausea and abdominal discomfort are possible; severe or bloody diarrhoea during or after treatment needs medical review. Renal impairment may increase exposure. Concomitant medicines, including anticoagulants, require a medication review. Seek urgent help for breathing difficulty, facial swelling or a widespread blistering rash.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes an oral capsule. Capsule shell, fill composition and release behavior are product-specific and are not established by the ingredient name. Opening a capsule or dispersing its contents should be considered only when the approved instructions or a pharmacist confirms that this is appropriate.
Retain the original labeled pack and check its integrity and expiry before use. Storage requirements must come from the supplied product information; no shelf life or temperature is inferred here. A pharmacist can advise on an alternative presentation if swallowing is difficult.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specifications/formula for each strength.
Approved label/leaflet with administration and safety information.
Pack/SKU matrix and artwork.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: CephalexinArchived source classification: US National Library of Medicine medicine reference | Source revision recorded: Last revised 15 June 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-028.
Professional enquiries
Request product-specific evidence for LP-028.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.